Skip to main content

Advertisement

SpringerLink
Log in

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Foucar K, Raber M, Foucar E, Barlogie B, Sandler CM, Alexanian R (1983) Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer 51(1):166–174. https://doi.org/10.1002/1097-0142(19830101)51:1<166::aid-cncr2820510132>3.0.co;2-7

    Article  CAS  PubMed  Google Scholar 

  2. Saburi M, Ogata M, Soga Y, Kondo Y, Kurimoto R, Itani K, Kohno K, Uchida H, Nakayama T (2020) Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma. J Clin Exp Hematop 60(1):17–20. https://doi.org/10.3960/jslrt.19031

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ammannagari N, Celotto K, Neppalli V, Lee K, Holstein SA (2016) Anaplastic multiple myeloma: an aggressive variant with a poor response to novel therapies. Clinical Lymphoma Myeloma and Leukemia 16(9):e129–e131. https://doi.org/10.1016/j.clml.2016.06.008

    Article  Google Scholar 

  4. Sethi S, Miller I (2016) Plasma cell myeloma with anaplastic transformation. Blood 128(16):2106. https://doi.org/10.1182/blood-2016-08-731844

    Article  CAS  PubMed  Google Scholar 

  5. Huang JX, Meng FJ, Feng XQ, Lyu X, Wang X (2020) Clinical and histopathological analyses of anaplastic myeloma. Chin Med J (Engl) 133(13):1614–1616. https://doi.org/10.1097/CM9.0000000000000902

    Article  Google Scholar 

  6. Bahmanyar M, Qi X, Chang H (2013) Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications. Leuk Res 37(12):1726–1728. https://doi.org/10.1016/j.leukres.2013.09.025

    Article  CAS  PubMed  Google Scholar 

  7. Qi CF, Shin DM, Li Z, Wang H, Feng J, Hartley JW, Fredrickson TN, Kovalchuk AL, Morse HC 3rd (2010) Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice. J Pathol 221(1):106–116. https://doi.org/10.1002/path.2692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ichikawa S, Fukuhara N, Hatta S, Himuro M, Nasu K, Ono K, Okitsu Y, Kobayashi M, Onishi Y, Ri M, Ichinohasama R, Harigae H (2018) Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop 58(1):39–42. https://doi.org/10.3960/jslrt.17035

    Article  PubMed  PubMed Central  Google Scholar 

  9. Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE, Ambinder RF, Ghosh N (2014) Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma. Ann Hematol 93(7):1245–1246. https://doi.org/10.1007/s00277-013-1950-7

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was funded by the Support Program of the Department of Science and Technology of Sichuan Province, China (2017SZ0194).

Author information

Authors and Affiliations

  1. Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China

    Wenjiao Tang, Yangfan Xu & Bing Xiang

Authors
  1. Wenjiao Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yangfan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bing Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and manuscript draft were performed by Wenjiao Tang and Yangfan Xu. Bing Xiang designed and revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Bing Xiang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of West China Hospital, Sichuan University.

Consent to participate

A written informed consent was obtained from the patient.

Consent to publish

The authors affirm that the patient has consented to the submission of the case report to the journal.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W., Xu, Y. & Xiang, B. Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy. Ann Hematol 100, 3039–3040 (2021). https://doi.org/10.1007/s00277-020-04244-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04244-7

Search

Navigation